Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income from Continuing Operations (2016 - 2025)

IGC Pharma (IGC) has disclosed Income from Continuing Operations for 16 consecutive years, with 1821000.0 as the latest value for Q3 2025.

  • Quarterly Income from Continuing Operations fell 6.06% to 1821000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 6446000.0 through Sep 2025, up 48.72% year-over-year, with the annual reading at 7121000.0 for FY2025, 45.22% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 1821000.0 at IGC Pharma, down from 1599000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 1197000.0 in Q1 2025, with the low at 6503000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 2790105.26, with a median of 2381000.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations tumbled 162.16% in 2021, then surged 67.28% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 2381000.0 in 2021, then increased by 5.54% to 2249000.0 in 2022, then plummeted by 148.51% to 5589000.0 in 2023, then soared by 67.28% to 1829000.0 in 2024, then grew by 0.44% to 1821000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1821000.0, 1599000.0, and 1197000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.